Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Ost

Showing results (141-150 of 334) with videos related to

Pageof 34
Sort By:
Radiation Oncology (London, England)|June 13, 2014
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrenceKarel Decaestecker, Gert De Meerleer, Bieke Lambert, et al.
Current Oncology Reports|March 29, 2019
Trends in Management of Oligometastatic Hormone-Sensitive Prostate CancerGargi Kothari, Piet Ost, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2018
Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic MelanomaNora Sundahl, Katrien De Wolf, Vibeke Kruse, et al.
Clinical Genitourinary Cancer|September 8, 2018
Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in BelgiumValérie Fonteyne, Elke Rammant, Piet Ost, et al.
European Urology|December 4, 2018
Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment TemplatesAurélie De Bruycker, Elise De Bleser, Karel Decaestecker, et al.
Molecular Imaging and Biology|April 12, 2022
Impact of <sup>18</sup>F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : <sup>18</sup>F-PSMA-11 PET/CT and Impact on Prostate Cancer ManagementKathia De Man, Sarah Piron, Nick Van Laeken, et al.
BMC Urology|February 5, 2021
A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillanceSamuel W D Merriel, Daniel Moon, Phil Dundee, et al.
European Urology Oncology|October 25, 2022
Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary CancersMai Anh Huynh, Chad Tang, Shankar Siva, et al.
European Urology Focus|September 26, 2022
Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER TrialValérie Fonteyne, Charles Van Praet, Piet Ost, et al.
Current Opinion in Oncology|January 30, 2019
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?Pauline De Bruyn, Dirk Van Gestel, Piet Ost, et al.
Pageof 34

Showing results (141-150 of 334) with videos related to

Sort By:
Pageof 34
Radiation Oncology (London, England)|June 13, 2014
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrenceKarel Decaestecker, Gert De Meerleer, Bieke Lambert, et al.
Current Oncology Reports|March 29, 2019
Trends in Management of Oligometastatic Hormone-Sensitive Prostate CancerGargi Kothari, Piet Ost, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2018
Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic MelanomaNora Sundahl, Katrien De Wolf, Vibeke Kruse, et al.
Clinical Genitourinary Cancer|September 8, 2018
Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in BelgiumValérie Fonteyne, Elke Rammant, Piet Ost, et al.
European Urology|December 4, 2018
Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment TemplatesAurélie De Bruycker, Elise De Bleser, Karel Decaestecker, et al.
Molecular Imaging and Biology|April 12, 2022
Impact of <sup>18</sup>F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : <sup>18</sup>F-PSMA-11 PET/CT and Impact on Prostate Cancer ManagementKathia De Man, Sarah Piron, Nick Van Laeken, et al.
BMC Urology|February 5, 2021
A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillanceSamuel W D Merriel, Daniel Moon, Phil Dundee, et al.
European Urology Oncology|October 25, 2022
Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary CancersMai Anh Huynh, Chad Tang, Shankar Siva, et al.
European Urology Focus|September 26, 2022
Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER TrialValérie Fonteyne, Charles Van Praet, Piet Ost, et al.
Current Opinion in Oncology|January 30, 2019
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?Pauline De Bruyn, Dirk Van Gestel, Piet Ost, et al.
Pageof 34